1
|
Chini B, Leonzino M, Braida D, Sala M. Learning about oxytocin: pharmacologic and behavioral issues. Biol Psychiatry 2014; 76:360-6. [PMID: 24120095 DOI: 10.1016/j.biopsych.2013.08.029] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2013] [Revised: 07/10/2013] [Accepted: 08/18/2013] [Indexed: 12/14/2022]
Abstract
Despite the accumulating evidence suggesting that the neuropeptide oxytocin (OT) plays a role in neuropsychiatric disorders characterized by social dysfunction, the influence of OT on the nonsocial aspects of learning and memory have been less investigated. To foster research in this area, we review the effects of OT on learning and memory in animal models and humans. In healthy animal models, OT improves memory consolidation and extinction, but only if given at a low dose immediately after the acquisition phase. On the contrary, OT effects in healthy humans have been inconsistent; although, in this case, OT was always given before the acquisition phase and no dose-response curves have ever been drawn up. Interestingly, a specific impairment in the reversal of learning has been found in mice devoid of OT receptors and OT has been demonstrated to enhance fear extinction in rodents. All together, these data suggest that OT plays a role in elementary forms of behavioral flexibility and adaptive responses and support its therapeutic potential in neuropsychiatric disorders characterized by cognitive inflexibility and/or impairment (autism, schizophrenia, Alzheimer's disease, Parkinson disease, stroke, posttraumatic stress disorder). Accordingly, OT has been shown to improve cognitive flexibility in OT receptor-deficient mice, and scattered findings indicate that intranasal OT has positive effects on the memory of patients with schizophrenia or posttraumatic stress disorders. Further studies of the therapeutic potential of OT as an enhancer of learning and memory are warranted.
Collapse
Affiliation(s)
- Bice Chini
- National Research Council, Institute of Neuroscience, Università degli Studi di Milano, Milan, Italy
| | - Marianna Leonzino
- National Research Council, Institute of Neuroscience, Università degli Studi di Milano, Milan, Italy; Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy
| | - Daniela Braida
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Don Gnocchi, Milan, Italy
| | - Mariaelvina Sala
- National Research Council, Institute of Neuroscience, Università degli Studi di Milano, Milan, Italy; Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy.
| |
Collapse
|
2
|
Abstract
Mild cognitive impairment (MCI) is an aspect of cognitive aging that is considered to be a transitional state between normal aging and the dementia into which it may convert. Appropriate animal models are necessary in order to understand the pathogenic mechanisms of MCI and develop drugs for its treatment. In this review, we identify the features that should characterize an animal model of MCI, namely old age, subtle memory impairment, mild neuropathological changes, and changes in the cholinergic system, and the age at which these features can be detected in laboratory animals. These features should occur in aging animals with normal motor activity and feeding behavior. The animal models may be middle-aged rats and mice, rats with brain ischemia, transgenic mice overexpressing amyloid precursor protein and presenilin 1 (tested at an early stage), or aging monkeys. Memory deficits can be detected by selecting appropriately difficult behavioral tasks, and the deficits can be associated with neuropathological alterations. The reviewed literature demonstrates that, under certain conditions, these animal species can be considered to be MCI models, and that cognitive impairment in these models responds to drug treatment.
Collapse
Affiliation(s)
- Giancarlo Pepeu
- Department of Pharmacology, University of Florence, Florence, Italy
| |
Collapse
|
3
|
Gravett N, Bhagwandin A, Fuxe K, Manger PR. Nuclear organization and morphology of cholinergic, putative catecholaminergic and serotonergic neurons in the brain of the rock hyrax, Procavia capensis. J Chem Neuroanat 2009; 38:57-74. [DOI: 10.1016/j.jchemneu.2009.02.005] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2009] [Revised: 02/18/2009] [Accepted: 02/27/2009] [Indexed: 11/28/2022]
|
4
|
Bartus RT, Dean RL. Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology (Berl) 2009; 202:15-36. [PMID: 19011839 DOI: 10.1007/s00213-008-1365-7] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2008] [Accepted: 10/02/2008] [Indexed: 12/21/2022]
Abstract
RATIONALE Over 30 years ago, we began to develop a nonhuman primate model to study cognitive deficits of age-related neurodegenerative diseases and their neuroanatomical-neurochemical underpinnings for purposes of translating this work toward first pharmacotherapies. This effort produced several notable findings that eventually received consensus support, which we have been asked to review. OBJECTIVES A discussion of these findings, in the context of issues and obstacles confronted and principles applied, might facilitate the development of even more effective models and treatments, not only for Alzheimer's disease (AD) but for many other disorders involving cognitive deficits. RESULTS Collectively, our research provided first evidence of the following: aged primates can be used as 'models' for human age-related neurodegenerative diseases; key cognitive deficits in early AD share important conceptual similarities to deficits in both aged monkeys as well as non-demented humans (e.g., age-associated memory impairment and mild cognitive impairment); pharmacological intervention can reduce age-related cognitive impairments in animals that are conceptually similar to those seen in human diseases, including AD; cholinergics would likely be the first approved therapeutics for AD; and that many other classes of drugs would not likely succeed. CONCLUSIONS Despite the early promise shown by behavioral/functional approaches to develop treatment strategies, the dramatic shift in focus away from behavioral outcomes in animal neurodegenerative research that began 20 years ago has compromised further progress and continues to impede our ability to understand how these diseases impair human cognition and what pathways might lead to effective therapies. Principles applied successfully in the past should provide guidance for facilitating efforts in the future.
Collapse
Affiliation(s)
- Raymond T Bartus
- Ceregene, Inc., 9381 Judicial Dr., Suite 130, San Diego, CA 92121, USA.
| | | |
Collapse
|
5
|
Jakubík J, El-Fakahany EE, Dolezal V. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors. Mol Pharmacol 2006; 70:656-66. [PMID: 16675658 DOI: 10.1124/mol.106.023762] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Xanomeline is a functionally selective M(1)/M(4) muscarinic acetylcholine receptor agonist that nevertheless binds with high affinity to all five subtypes of muscarinic receptors. A novel mode of interaction of this ligand with the muscarinic M(1) receptors characterized by persistent binding and receptor activation after extensive washout has been shown previously. In the present study, using human M(1) and M(2) receptors expressed in Chinese hamster ovary cells and [(3)H]N-methylscopolamine as a tracer, we show that persistent binding of xanomeline also occurs at the M(2) receptor with similar affinity as at the M(1) receptor (K(I) = 294 and 296 nM, respectively). However, kinetics of formation of xanomeline wash-resistant binding to M(2) receptors was markedly slower than to M(1) receptors. Xanomeline was a potent fast-acting full agonist in stimulating guanosine 5'-O-(3-[(35)S]thio)triphosphate binding at M(1) receptors, whereas at M(2) receptors it behaved as a potent partial agonist (40% of carbachol maximal response) only upon preincubation for 1 h. Development of xanomeline agonistic effects at the M(2) receptor was slower than its ability to attenuate carbachol responses. We also demonstrate that xanomeline discriminates better between G protein subtypes at M(1) than at M(2) receptors. Our data support the notion that xanomeline interacts with multiple sites on the muscarinic receptor, resulting in divergent conformations that exhibit differential effects on ligand binding and receptor activation. These conformations are both time- and concentration-dependent and vary between the M(1) and the M(2) receptor.
Collapse
Affiliation(s)
- Jan Jakubík
- Department of Neurochemistry, Institute of Physiology CAS, Vídenská 1083, 14220 Prague, Czech Republic.
| | | | | |
Collapse
|
6
|
|
7
|
Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163:495-529. [PMID: 10833325 DOI: 10.1006/exnr.2000.7397] [Citation(s) in RCA: 552] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Life's Journey If life is indeed a journey, then poetry must be the map that reveals all its topographic possibilitiesellipsis while science is the compass that keeps us from getting lost. -R. T. Bartus, Simple Words for Complex Lives, (c) 1998 In the nearly 20 years since the cholinergic hypothesis was initially formulated, significant progress has been achieved. Initial palliative treatments for Alzheimer's disease (AD) have proven beneficial and have gained FDA approval, the use of animal models for studying AD and other neurodegenerative diseases has achieved wider acceptance, and important insight into the potential causes and pathogenic variables associated with various neurodegenerative diseases continues to increase. This paper reviews the current status of the cholinergic hypothesis in the context of continuing efforts to improve upon existing treatments for AD and explores the role that animal models might continue to play. Using the benefit of hindsight, particular emphasis is placed on an analysis of the approaches, strategies, and assumptions regarding animal models that proved useful in developing the initial treatments and those that did not. Additionally, contemporary issues of AD are discussed within the context of the cholinergic hypothesis, with particular attention given to how they may impact the further refinement of animal models, and the development of even more effective treatments. Finally, arguments are presented that, despite the deserved enthusiasm and optimism for identifying means of halting the pathogenesis of AD, a clear need for more effective palliative treatments will continue, long after successful pathogenic treatments are available. This review, therefore, focuses on issues and experiences intended to: (a) facilitate further development and use of animal models for AD and other neurodegenerative diseases, and (b) accelerate the identification of newer, even more effective treatments.
Collapse
Affiliation(s)
- R T Bartus
- Preclinical R&D, Alkermes, Inc., 64 Sidney Street, Cambridge, Massachusetts 02139, USA
| |
Collapse
|
8
|
Diaz Brinton R. Vasopressin in the mammalian brain: the neurobiology of a mnemonic peptide. PROGRESS IN BRAIN RESEARCH 1999; 119:177-99. [PMID: 10074789 DOI: 10.1016/s0079-6123(08)61570-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
We have sought to understand the mechanisms by which VP can enhance memory function and in the process determine whether VP fulfills the requirements for neurotransmitter status. The latter goal of proving the neurotransmitter status of VP has been achieved through our findings and the results of many of the scientists contributing to this volume. With respect to elucidating the mechanisms by which VP can enhance memory function, results of our work have shown that VP and its receptors are present in brain regions known to be involved in memory function, that release of VP is inhibited by a factor that inhibits memory function, that VP can significantly enhance the morphological complexity and outgrowth of neurons involved in memory function, that second messenger systems held to be involved in learning and memory, cyclic AMP and calcium signaling pathways, are potentiated and activated by VP, that electrophysiological models of memory function are induced by VP, and that when animals remember a learned association VP content in brain increases over time during the active phase of remembering. Collectively, these studies have taught us a great deal about the sites and mechanisms of VP action and have led us to pursue avenues of investigation that we would not have imagined 15 years ago when we began this work. We stand on the threshold of a new era in our research as we begin our studies of the role VP and its receptors play in the cerebral cortex. Thus far, results of these studies are quite exciting and promise to yield fascinating insights into the complexities of VP action in the most highly developed region of the mammalian brain, the cerebral cortex, the site of abstract reasoning, judgment, complex analysis and the repository of those memories that last a life-time.
Collapse
Affiliation(s)
- R Diaz Brinton
- Department of Molecular Pharmacology and Toxicology, USC Pharmaceutical Sciences Center, Los Angeles, USA
| |
Collapse
|
9
|
Abstract
Aging in humans may be accompanied by alterations in several functional abilities. However, there is a great deal of individual variability in the functions that may be altered with age within and across aged people. One potential source of age-related behavioral variation may lie in a differential vulnerability of neurobiological systems to the aging process in particular individuals. Aged monkeys demonstrate behavioral and brain alterations that have many parallels with those observed in aged humans and are valuable animal models in which to investigate the interrelationships between age, behavior and neurobiological measures. This review outlines the similarities of functional and neurobiological aging in monkeys and humans, notes the variability that exists in both behavioral and neural systems in aging, and identifies some of the areas of aging that are in need of further investigation.
Collapse
|
10
|
Abstract
Experimental pharmacotherapy of cognitive impairment in Alzheimer's disease has seen a recent proliferation of drug trials involving a wide variety of drugs. Many of the earlier studies focused on cholinergic agents. However, subsequent advances in basic and biological sciences have broadened the scope of therapeutic strategies beyond the neurotransmitter approaches to include neurotrophic, metabolic-enhancing, membrane-modifying, and antitoxic agents, and have also provided rationale for developing antiamyloid and anti-infective therapies. For the clinician, it has not been easy to keep abreast of these developments. In this article, I present an overview of the cognition-enhancing drugs that have been used in the past, of those currently under investigation, and of new drugs and strategies that are likely to receive attention in the next few years.
Collapse
Affiliation(s)
- S V Patel
- Department of Psychiatry, University of Rochester School of Medicine and Dentistry, New York, USA
| |
Collapse
|
11
|
Hasenöhrl RU, Frisch C, Nikolaus S, Huston JP. Chronic administration of neurokinin SP improves maze performance in aged Rattus norvegicus. BEHAVIORAL AND NEURAL BIOLOGY 1994; 62:110-20. [PMID: 7527633 DOI: 10.1016/s0163-1047(05)80032-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Deficits in associative functions seen with senescence may be based, at least in part, on a decreased availability of trophic factors in the CNS. A reduced concentration of neurokinins, including undecapeptide substance P (SP), also accompanies aging. Thus, given the change in SP metabolism and the known mnemogenic as well as neurotrophic/neuroprotective effects of the peptide, it seems possible that age-related deficits in associative processes could be influenced by treatment with exogenous SP. In the present study, 30-month-old Wistar rats were injected daily with SP (50 or 250 micrograms/kg, intraperitoneally) starting 1 week before they were tested on the Morris water maze task and on motor coordination tests. Control groups included vehicle-injected old and adult (3-month-old) rats. Over the days of maze testing, application of the substances was performed 5 h after testing daily for 15 days and after the last drug delivery, maze testing was continued for 4 more days. The main finding of this study is that chronic administration of both dosages of SP (50 and 250 micrograms/kg) improved the maze performance of the old rats. This facilitatory effect of SP on performance was also evident after the drug treatment had been terminated in the course of maze testing. Furthermore, chronic application of SP in a dose range of 50-250 micrograms/kg was found to reduce age-related deficits in motor capacities.
Collapse
Affiliation(s)
- R U Hasenöhrl
- Institute of Physiological Psychology I, Heinrich-Heine-University Düsseldorf, Germany
| | | | | | | |
Collapse
|
12
|
Abstract
The hypothalamic peptide hormones, TRH, LHRH (GnRH), CRH, GHRH, and GHIRH (somatostatin), influence the release of the anterior pituitary hormones, which in turn promote the release of target endocrine gland hormones and other metabolites. These latter compounds feed back to the brain to help control the secretion of the hypothalamic hormones. This is a dynamic interaction that is influenced by the aging process: Most of these hormones systems become less responsive with advancing age, due to decreased function of peptide-containing secretory neurons, a loss of hormone receptor sensitivity, and/or a reduction in the output of the target endocrine glands. That the hypothalamic peptides themselves can influence brain function is supported by the fact that most are found in areas of the brain other than the hypothalamus and that receptors for them exist in these other areas. For example, CRH is contained in a number of central neural systems that can influence behavior, including limbic areas, the hypothalamus, locus coeruleus, median raphé nuclei, and cortical interneurons. CRH has been shown to be anxiogenic in animal models, and its effect can be blocked by CRH receptor antagonists. CRH content in the locus coeruleus is particularly increased by stress and may influence norepinephrine neurotransmitter function in this structure. In aging there is a gradual reduction of the sensitivity of the brain to the negative feedback of corticosteroids, such that CRH secretion becomes somewhat increased under basal conditions. The behavioral effects of this change are unclear, however, as is the influence of stress-related activation of CRH, ACTH, and glucocorticoid secretion on behavior in the elderly. Other hypothalamic peptides have different patterns of change with aging, and some are markedly altered in pathological conditions; for example, in Alzheimer's disease the content of CRH and somatostatin in certain brain areas is decreased. However, whether the changes in hypothalamic peptides precede or follow the pathological behavioral changes, and how they participate in the changes, is still unclear.
Collapse
Affiliation(s)
- T F Sadow
- Department of Psychiatry, Harbor-U.C.L.A. Medical Center, Torrance
| | | |
Collapse
|
13
|
Bartus RT. Drugs to treat age-related neurodegenerative problems. The final frontier of medical science? J Am Geriatr Soc 1990; 38:680-95. [PMID: 1972712 DOI: 10.1111/j.1532-5415.1990.tb01430.x] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- R T Bartus
- Cortex Pharmaceuticals, Inc., Irvine, California 92718
| |
Collapse
|
14
|
Bartus RT. The need for common perspectives in the development and use of animal models for age-related cognitive and neurodegenerative disorders. Neurobiol Aging 1988; 9:445-51. [PMID: 3062456 DOI: 10.1016/s0197-4580(88)80097-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Research toward the development and use of animals models of age-related neurodegeneration and memory loss has accelerated rapidly during the past decade. However, the degree to which various investigators have been able to integrate their findings has not kept pace. Given the apparent complexity of neurodegenerative and cognitive phenomena, it seems essential that more effective dialogue between investigators with diverse backgrounds and approaches be achieved. Such a dialogue would likely reduce certain confusion and misunderstanding that currently exist in this field. It might also be expected that the dialogue would lead to the development of a working framework for continued growth and integration of novel findings and ideas. This paper attempts to promote a dialogue by identifying and discussing certain broad issues that produce unnecessary confusion in the common pursuit of using animals to understand various aspects of complex human neurodegenerative diseases. Also, some perspectives are suggested that may facilitate discussion and comparison of different animal models, independent of the paradigms and species used.
Collapse
Affiliation(s)
- R T Bartus
- CORTEX Pharmaceuticals, Inc., Costa Mesa, CA 92626
| |
Collapse
|
15
|
Mundy WR, Iwamoto ET. Studies on desglycinamide arginine vasopressin and scopolamine in a modified/lever-touch autoshaping model of learning/memory in rats. Pharmacol Biochem Behav 1987; 27:307-15. [PMID: 3628445 DOI: 10.1016/0091-3057(87)90574-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Vasopressin administration has been reported to improve acquisition and retard extinction of both conditioned avoidance and food-reinforced behavioral tasks. In the present experiment the effects of a vasopressin analog (DGAVP) and scopolamine (SCOP) were tested in an autoshaped lever-touch model of learning and memory. Rats were food-deprived to 80% of original body weights and tested in modular cages which contained a retractable lever that was presented on a random interval 48 sec schedule. The lever retracted after 15 sec or when it was touched, at which time one 45 mg food pellet was delivered. Subcutaneous injection of 10 micrograms/kg DGAVP 1 hr prior to acquisition and extinction sessions did not alter responding compared to saline controls. DGAVP at doses of 10, 20, and 30 micrograms/kg also failed to affect responding in a more difficult task which included an 8 sec delay between lever retraction and reinforcement. Homozygous Brattleboro rats, which are deficient in vasopressin, did not differ from normal heterozygous littermates in the acquisition of the lever-touch response. Intraperitoneal injection of SCOP (0.1-0.8 mg/kg) 30 min prior to testing caused a dose-related impairment of acquisition compared to saline controls, but did not alter responding in animals which had previously acquired the lever-touch response. These data suggest that manipulations of vasopressin do not affect, while SCOP impairs, the acquisition of a positively reinforced lever-touch response in rats.
Collapse
|
16
|
|
17
|
Abstract
Vasopressin (AVP) has been identified as a neural peptide which may influence memory function. Because of this action, we investigated the effect of AVP on neurons growing in culture. Vasopressin was found to markedly increase neurite outgrowth from cultured embryonic neurons and to also accelerate the rate of neuritic growth. Maximal stimulation of neurite production occurred after 24-hour incubation in the presence of 1 microM AVP. In AVP-treated cultures the profuse neuritic arborization was characterized by numerous microspikes along the neuritic shafts and at the perimeters of growth cones. These data provide strong evidence for a neurotrophic effect of AVP which, we suggest, may be relevant to neuronal development as well as to morphological changes which occur in the mature nervous system, possibly during memory formation.
Collapse
Affiliation(s)
- R E Brinton
- Department of Pharmacology, University of Arizona College of Medicine, Tucson 85724
| | | |
Collapse
|
18
|
Hinko A, Pearlmutter AF. Effects of arginine vasopressin on protein phosphorylation in rat hippocampal synaptic membranes. J Neurosci Res 1987; 17:71-9. [PMID: 3033258 DOI: 10.1002/jnr.490170111] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Our laboratory has reported previously the characteristics of specific AVP binding to rat hippocampal synaptic membranes (SPM) in the presence of Ni2+ [Costantini MG, Pearlmutter AF: J Biol Chem 259: 11739-11745, 1984]. We extended our investigation to determine the effects of Ni2+, (AVP), and AVP analogs on SPM protein phosphorylation. Ni2+ (5 mM) caused a dramatic reduction in phosphorylation of most SPM phosphoproteins. The most prominent protein which is phosphorylated in SPM has a molecular weight of 48 kilodaltons (KDa) and has been named B50 or F1; this protein shows altered phosphorylation in vitro in response to long-term potentiation in vivo as well as changes induced by exposure of SPM to ACTH (1-24), dopamine, and somatostatin. AVP and related peptides reduced phosphorylation of this pre-synaptic phosphoprotein in the following order of potency: AVP = oxytocin greater than DG-AVP greater than dDAVP greater than d(CH2)5Tyr(Me)AVP = [pGlu4,Cyt6]AVP-(4-9). Except for the pressor antagonist d(CH2)5Tyr(Me)AVP, this corresponds to their relative efficacy in displacing 3H-AVP from high-affinity specific binding sites on rat hippocampal synaptic membranes. Ni2+ did not alter the degree of inhibition caused by the peptides. When SPM were treated with AVP after the attainment of maximum 32P incorporation, AVP inhibited dephosphorylation over a 30-min period. Our results show that AVP can alter both phosphorylation and dephosphorylation of hippocampal SPM phosphoproteins in vitro; the direction of these effects depends upon experimental conditions. Since B50/F1 is known to be a substrate for protein kinase C, AVP may act by inhibition of protein kinase C activity, either directly or indirectly.
Collapse
|
19
|
Brinton RE, Gruener R, Deshmukh P, Yamamura HI. In vitro inhibition of vasopressin release in brain by behaviorally relevant ethanol concentrations. Neurosci Lett 1986; 67:213-7. [PMID: 3725210 DOI: 10.1016/0304-3940(86)90400-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We have investigated the effect of ethanol upon vasopressin (AVP) content in brain and upon in-vitro release of AVP from the rat median eminence. In-vitro ethanol concentrations (5-25 mM), comparable to behaviorally relevant blood ethanol levels, induce a substantial inhibition of AVP release from the median eminence, whereas higher ethanol concentrations (greater than 50 mM) potentiate release. In vivo, ethanol, at a behaviorally relevant blood ethanol concentration (126 mg%), does not produce a significant difference in AVP content in brain although there is a consistent trend towards an increase in the hypothalamus and neurohypophysis. The results are considered in relation to the effects of ethanol on biogenic amine release and to memory impairments induced by low doses of acute ethanol exposure.
Collapse
|
20
|
Miller LH, Turnbull BA. The effect of MSH/ACTH 4-10 on delayed response performance and post-test locomotor activity in rats. Peptides 1986; 7:201-5. [PMID: 3016679 DOI: 10.1016/0196-9781(86)90213-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Delayed response performance was measured in male, Long-Evans rats 1 hr after IP administration of various doses of MSH/ACTH 4-10 or control in a Hunter delayed reaction apparatus. Additional treatments consisting of naloxone 500 micrograms/kg (IP) and naloxone 500 micrograms/kg in conjunction with MSH/ACTH 4-10 95 micrograms/kg were also administered. Directly after delayed response performance was assessed, gross locomotor activity was determined. MSH/ACTH 4-10, at a dose of 95 micrograms/kg, significantly enhanced retention of a visual stimulus, while MSH/ACTH 4-10, at doses of 195 and 285 micrograms/kg, significantly impaired delayed response performance. Naloxone treatment resulted in significantly impaired delayed response performance when compared to control. However, naloxone plus MSH/ACTH 4-10 treatment failed to produce a significant difference from control in the delayed response performance paradigm. In post-test locomotor activity determination, an apparent dose-response existed for MSH/ACTH 4-10 with the two highest doses (190 and 285 micrograms/kg) resulting in significantly increased locomotor activity. The observed delayed response performance data support theories implicating MSH/ACTH peptides in attentional processes involving visual stimuli. The fact that large doses of MSH/ACTH 4-10 disrupt delayed response performance while increasing post-test activity suggest that an optimum level of effect caused by the MSH/ACTH peptide exists in this paradigm.
Collapse
|
21
|
Abstract
This review critically evaluates the animal and human research concerning vasopressin's putative mnemonic role. Weaknesses in the interpretations of the early animal experiments as well as the implications of the later inconsistent findings are discussed. It is concluded that both the initial enthusiasm and the subsequent skepticism concerning this hypothesized role were premature. This conclusion applies equally to the human research. A review of these studies reveals that almost all of the negative reports involved cognitively-impaired individuals. The relatively few studies that have been conducted concerning vasopressin's effects in unimpaired human subjects are consistent with the hypothesis that vasopressin does affect cognition, though both the mechanism of action and the specific cognitive processes which are altered have yet to be elucidated.
Collapse
|
22
|
Pontecorvo MJ, Evans HL. Effects of aniracetam on delayed matching-to-sample performance of monkeys and pigeons. Pharmacol Biochem Behav 1985; 22:745-52. [PMID: 4011635 DOI: 10.1016/0091-3057(85)90523-4] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
A 3-choice, variable-delay, matching-to-sample procedure was used to evaluate drugs in both pigeons and monkeys while tested under nearly-identical conditions. Aniracetam (Roche 13-5057) improved accuracy of matching at all retention intervals following oral administration (12.5, 25 and 50 mg/kg) to macaque monkeys, with a maximal effect at 25 mg/kg. Aniracetam also antagonized scopolamine-induced impairment of the monkey's performance. Intramuscular administration of these same doses of aniracetam produced a similar, but not significant trend toward improved matching accuracy in pigeons.
Collapse
|
23
|
|
24
|
|
25
|
Brinton RE, Gee KW, Wamsley JK, Davis TP, Yamamura HI. Regional distribution of putative vasopressin receptors in rat brain and pituitary by quantitative autoradiography. Proc Natl Acad Sci U S A 1984; 81:7248-52. [PMID: 6095279 PMCID: PMC392116 DOI: 10.1073/pnas.81.22.7248] [Citation(s) in RCA: 70] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Quantitative light microscopic autoradiography was used to map and characterize the distribution of [3H]arginine vasopressin [( 3H]AVP) binding sites in the rat brain. HPLC analysis for possible degradation of AVP during binding indicated that addition of specific peptidase inhibitors prevented metabolism of AVP. Binding sites for [3H]AVP were observed in the hypothalamus and pituitary as well as in brain regions where AVP may act as a neuroregulator. Within the hypothalamus, dense AVP binding sites were seen in the suprachiasmatic, supraoptic, and paraventricular nuclei. High specific binding was also apparent in the median eminence tubero-infundibular region and in the posterior lobe of the pituitary. [3H]AVP labeling at possible neuroregulatory sites was observed in the hippocampus, lateral septum, superficial cortex, cerebellum, nucleus tractus solitarious, adenohypophysis, and spinal cord.
Collapse
|
26
|
Crine AF. Vasopressin effects on food-rewarded learning tasks might be due to its action on carbohydrate/lipid metabolism, not memory. Appetite 1984; 5:233-8. [PMID: 6524919 DOI: 10.1016/s0195-6663(84)80018-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Vasopressin (VP) has been implicated in memory processes on the basis of effects observed in aversively motivated learning situations. Therefore researchers have tried to confirm this role by using food-motivated learning tasks. However, the well-established physiological influences of VP on carbohydrate and lipid metabolism were not taken into consideration. At various times following administration, VP might act as a feeding stimulant or as a satiating agent. Experimental designs should allow for these effects when food-rewarded learning paradigms are used to determine whether VP acts on memory.
Collapse
|
27
|
Siegfried B, Frischknecht HR, Waser PG. Vasopressin impairs or enhances retention of learned submissive behavior in mice depending on the time of application. Behav Brain Res 1984; 11:259-69. [PMID: 6539117 DOI: 10.1016/0166-4328(84)90218-3] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The effects of vasopressin on learning and memory were investigated in a paradigm using adaptive capabilities of interacting male mice. Test animals of the DBA/2 strain which were not submissive in a confrontation with a non-aggressive subordinate C57BL/6 mouse on day 1 (baseline), were defeated on day 2 (learning) by an aggressive dominant C57 mouse, and showed learned submissive behavior upon mere contact with a non-aggressive C57 mouse on day 3 (retest). Pretrial injections of lysine-vasopressin (0.01, 0.1 or 1.0 I.U., s.c.) 20 min before defeat on day 2 resulted in less submissive behavior on day 3 compared to controls, with 0.1 I.U. (equal to 370 ng) being the most effective dose. Post-trial injections of vasopressin (0.1 I.U.) immediately after defeat on day 2 significantly improved retention on day 3. Preretention injections of vasopressin (0.1 I.U.) 20 min before testing on day 3 significantly increased learned submissive behavior. The amnesic effect observed after pretrial injections of vasopressin was neither due to state dependency nor to an acquisition deficit, nor to antinociception. It is concluded that processing of the stressful experience of defeat is differently influenced by vasopressin given before or after training, resulting in an impaired or facilitated retention, respectively. Among the hypothetically discussed underlying mechanisms, one suggestion is that exogenous vasopressin interacts with an assumed discriminative stimulus function of endogenously released vasopressin. Another possibility might be that exogenous vasopressin interferes with the defeat-activated opioid peptide system.
Collapse
|
28
|
|
29
|
Chapter 4. Cognitive Disorders. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1984. [DOI: 10.1016/s0065-7743(08)60680-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|
30
|
Yehuda S, Carasso RL. Changes in circadian rhythms of thermoregulation and motor activity in rats as a function of aging: effects of d-amphetamine and alpha-MSH. Peptides 1983; 4:865-9. [PMID: 6672792 DOI: 10.1016/0196-9781(83)90082-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Thermoregulatory and motor activity circadian cycles are age-dependent. While the level of thermoregulation and motor activity remained almost at the same level during the first 1-15 months during the light portion of the 24-hr cycle, a significant decrease in the level of both rhythms was observed during the dark period. Therefore, older rats exhibited reversed cycles compared with younger rats. Treatments with d-amphetamine resulted in the enhancement of reversal of the cycles. Rats treated with alpha-MSH failed to exhibit a reversal of the cycles. While the effects of d-amphetamine are mediated by the brain DA mesolimbic pathway, it seems that alpha-MSH acts on the dopaminergic system at different sites of action.
Collapse
|
31
|
Alliot J, Alexinsky T. Repeated post trial administration of vasopressin impairs subsequent Differential Reinforcement of Low rates (DRL) performance. Behav Processes 1983; 8:345-62. [DOI: 10.1016/0376-6357(83)90023-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/03/1983] [Indexed: 11/15/2022]
|
32
|
Messing RB, Sparber SB. Des-Gly-vasopressin improves acquisition and slows extinction of autoshaped behavior. Eur J Pharmacol 1983; 89:43-51. [PMID: 6861889 DOI: 10.1016/0014-2999(83)90606-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The effects of a vasopressin analog (DGAVP) with minimal endocrinological activity, were assayed on acquisition and extinction of a discrete trial, food reinforced, autoshaped lever touch response. Magazine-trained rats, maintained at 80-85% of free-feeding body weights, were injected s.c. with saline, 5 or 10 micrograms/kg of DGAVP 1 h before each of two sessions in which they learned to touch a retractable lever, presented on a 45 s random interval (RI 45) schedule. Retracted lever contacts (nose-pokes) and unconditioned rearing activity were simultaneously monitored. After acquisition of the extended lever touch response, rats were reassigned to treatment groups, and again injected with saline, 5 or 10 micrograms/kg of DGAVP 1 h before each of two extinction sessions. DGAVP facilitated acquisition (5 micrograms/kg) and slowed extinction (5 and 10 micrograms/kg) of conditioned behavior, while having no effects on the other behaviors, thus demonstrating the specificity of the effect of a vasopressin-like compound on both tasks (enhanced acquisition and retarded extinction) used to study learning.
Collapse
|
33
|
Abstract
Five pigeons were tested in a delayed matching-to-sample task after receiving an acute injection of DDAVP (1-desamino-8-D-arginine), scopolamine or d-amphetamine. A feeding test also was used to document non-specific drug effects. Scopolamine produced a marked dose-related decrement in accuracy of matching, regardless of delay, indicating that scopolamine impairs both discrimination and short-term memory. Neither DDAVP nor d-amphetamine produced consistent changes in delayed matching. Thus, an experimental model of short-term memory with pigeons did not confirm the findings of others of a positive effect of DDAVP upon cognitive performance in humans.
Collapse
|